Literature DB >> 1151014

Aspirin intolerance. III. Subtypes, familial occurence, and cross-reactivity with tartarazine.

G A Settipane, R K Pudupakkam.   

Abstract

Evidence has been presented supporting the hypothesis that at least 2 different types of mechanisms may be involved in aspirin intolerance, one resulting in bronchospasm and the other producing urticaria/angioedema. Bronchospasm is the predominant symptom of aspirin intolerance in patients who have asthma. In contrast, the predominant symptom of aspirin intolerance in patients who have rhinitis is urticaria/angioedema. In the bronchospastic type of aspirin intolerance, there is a significant correlation with an increased frequency of nasal polyposis, and with a similar ageonset of asthma and aspirin intolerance. These correlations were not present in the urticari/angioedema type. Additional evidence for familial occurrence of aspirin intolerance is presented, and its relationship with subtypes of aaspirin intolerance is discussed. In a double-blind, crossover study with normal control subjects matched by age and sex 15% (6/40) of aspirin-intolerant individuals had significant adverse reactions to tartrazine challenge and not to the placebo. None of the 40 normal control subjects had any adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1151014     DOI: 10.1016/0091-6749(75)90092-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  Tartrazine exclusion for allergic asthma.

Authors:  K D Ardern; F S Ram
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Asthma and anti-inflammatory drugs. Mechanisms and clinical patterns.

Authors:  A Szczeklik; R J Gryglewski
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

3.  Sensitivity to tartrazine.

Authors:  K Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-04

Review 4.  Genetics and pharmacogenetics of the leukotriene pathway.

Authors:  Kelan G Tantisira; Jeffrey M Drazen
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

5.  Tartrazine in atopic eczema.

Authors:  J Devlin; T J David
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

6.  Histopathological Examinations of nasal polyps of different etiology.

Authors:  C Baumgarten; G Kunkel; R Rudolph; R D Staud; I Sperner; H Gelderblom
Journal:  Arch Otorhinolaryngol       Date:  1980

Review 7.  Analgesics, allergy and asthma.

Authors:  A Szczeklik
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Intolerance to acetylsalicylic acid (aspirin) and tartrazine. Evidence of complement activation in a patient following oral challenge with tartrazine.

Authors:  V Voigtländer; I Moll; C Stach
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

9.  Reactions to dietary tartrazine.

Authors:  T J David
Journal:  Arch Dis Child       Date:  1987-02       Impact factor: 3.791

10.  Tartrazine: a potentially hazardous dye in Canadian drugs.

Authors:  M E MacCara
Journal:  Can Med Assoc J       Date:  1982-04-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.